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nary infusion of escalating doses of selected, autologous, bone
marrow AC133 cells are safe for use in humans with chronic
ischemia. We anticipate that these continued laboratory studies
will provide sound scientiﬁc rationale for future phase II and III
clinical studies in cardiovascular disease.
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ISOLATION AND CHARACTERIZATION OF UMBILICAL CORD BLOOD-
DERIVED MULTIPOTENT STEM CELLS ARISING FROM AN ADHERENT
CD45/CD34 CELL SUBSET
Collins, Daniel P. BioE, Inc., St. Paul, MN.
A number of groups have reported the presence of cells with
varying degrees of multi-lineage potential arising from a CD45/
CD34 cell population with a ﬁbroblastic morphology and char-
acteristics consistent with mesenchymal stem cells (MSC). This
study reports the identiﬁcation of stem cells distinct from MSCs
deriving from a plastic adherent CD45/CD34 population with
the ability to establish stable, readily expandable clones with ex-
tensive multi-lineage potential. Differentiation protocols have
been developed to induce conversion of multilineage precursor
cells (MLPCs) to adipocytes, osteocytes, chondrocytes, myocytes,
neural and glial cells, endothelial cells, lung epithelial cells and
hepato-pancreatic precursor cells. The ability of individual clonal
cell lines to differentiate into each of the described cell types
demonstrates the potential to derive tissue types consistent with all
three germinal layers. Molecular karyotyping and microarray anal-
ysis have shown the MLPC to be a normal diploid cell that is stable
through many doublings and is a very primitive cell, not committed
to speciﬁc lineages. MLPC do not spontaneously differentiate and
retain their morphology and phenotype throughout culture unless
speciﬁcally induced to differentiate. Early studies with extra-cellu-
lar matrices suggest a potential utility of MLPC in tissue engineer-
ing as well as a tool for target validation and toxicity testing in
pharmaceutical development.
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IMMUNE RECONSTITUTION AFTER UMBILICAL CORD BLOOD TRANS-
PLANTATION
Szabolcs, Paul. Duke University Medical Center, Durham, NC.
Unrelated cord blood transplantation (UCBT) has been increas-
ingly utilized for a wide variety of malignant and non-malignant
conditions. HLA-mismatching between cord blood grafts and their
recipients is better tolerated with a reduced risk for lethal graft
versus-host disease (GVHD) despite the adoptive transfer of sev-
eral million cord blood T cells/kg recipient weight. The almost
exclusively naïve, antigen inexperienced cord blood T lymphocytes
demonstrate functional immaturity providing the currently ac-
cepted mechanism responsible for this phenomenon. However,
infections within the ﬁrst 3-6 months after UCBT, remain the
major cause of morbidity and mortality. We will review key aspects
of neonatal immunity that reﬂect the immunoregulatory effects of
the feto-maternal interface. Multiple control mechanism exist here
impacting on both neonatal and maternal T lymphocytes that are
essential to sustain immune tolerance between fetus and mother.
Our current research efforts focus on elucidating the unique
biology of immune reconstitution after UCBT. Our guiding hy-
pothesis is that the kinetics and quality of immune recovery within the
ﬁrst 2 months after transplant are directly related to interactions
between the adoptively transferred T cells, host factors, and the
presence or absence of latent viral infections. These interactions in a
lymphopenic environment could inﬂuence and bias the emerging
T lymphocytes and dendritic cells post-UCBT. We have exten-
sively studied150 children, all unrelated cord blood recipients, in
our laboratory over the past years. Despite the presence of immu-
nosuppressive agents such as Cyclosporine A and corticosteroids
there is peripheral expansion and signiﬁcant maturation in the T
cell compartment already within the ﬁrst 3 weeks after UCBT.
Those experiencing or at risk for OI develop signiﬁcantly faster
towards an effector Th1/Tc1 phenotype and function, essential for
effective control of viral, fungal infections. In addition select fea-
tures of T cell activation and cytokine secretion proﬁle can identify
those who develop acute GVHD.
1227
